Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Research & Development (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Research & Development for 14 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 17.87% year-over-year to $3.7 million, compared with a TTM value of $12.4 million through Dec 2025, down 25.5%, and an annual FY2025 reading of $12.4 million, down 25.5% over the prior year.
  • Research & Development was $3.7 million for Q4 2025 at Heron Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $42.1 million in Q1 2022 and bottomed at -$13.7 million in Q4 2022.
  • Average Research & Development over 5 years is $14.3 million, with a median of $8.3 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 147.6% in 2022, then skyrocketed 156.76% in 2023.
  • Year by year, Research & Development stood at $28.9 million in 2021, then crashed by 147.6% to -$13.7 million in 2022, then skyrocketed by 156.76% to $7.8 million in 2023, then crashed by 59.27% to $3.2 million in 2024, then rose by 17.87% to $3.7 million in 2025.
  • Business Quant data shows Research & Development for HRTX at $3.7 million in Q4 2025, $3.5 million in Q3 2025, and $2.9 million in Q2 2025.